Thank you for subscribing!
Next Investors Archived Dec 19, 2019
One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).
Finfeed Archived Dec 17, 2019
Finfeed runs the ruler over the biotech stocks to watch in 2020.
Finfeed Archived Dec 11, 2019
PharmAust Ltd (ASX:PAA), a clinical-stage oncology company that’s developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymphoma.
Finfeed Archived Nov 29, 2019
The $3 million BPH Energy Ltd (ASX: BPH) has promising prospects with the ability to capitalise on the development of one or some of the assets held by Advent Energy.
Get expert stock analysis direct in your inbox
Archer Materials Limited (ASX:AXE) has informed the market that it will close its Share Purchase Plan (SPP) on Friday, December 6, 2019 at 5 PM eastern daylight saving time.
Finfeed Archived Nov 28, 2019
Shares in Prescient Therapeutics Limited (ASX:PTX) surged 50% on Wednesday after the clinical stage oncology company developing personalised medicine approaches to cancer released promising news.
Finfeed Archived Nov 26, 2019
Archer Materials Limited (ASX:AXE) has progressed its graphene-based biosensor technology development by building a first-phase prototype device to test the printing and performance of graphene inks.
Next Investors Archived Nov 25, 2019
Archer Materials (ASX:AXE) announced the successful and scalable assembly of qubit array components of the 12CQ room-temperature qubit processor.
Finfeed Archived Nov 19, 2019
Streamlining of the group’s internal operations and the pending Progenza licensing deal in Japan, will see Regeneus sufficiently funded to commercialisation in Japan.
Join Our Mailing List
